1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"RFA-HL-26-018: Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)" is currently closed and not accepting applications.
RFA-HL-26-018: Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). Provides early-stage translational support for developing therapeutic agents for heart, lung, blood, and sleep disorders, including diagnostics for respiratory diseases like tuberculosis.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-AI-26-003: Notice of NIAID Participation in RFA-HL-26-018, Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed) Notice of NIAID Participation in RFA-HL-26-018, Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed) National Institute of Allergy and Infectious Diseases ( NIAID ) This Notice informs potential applicants that the National Institute of Allergy and Infectious Diseases (NIAID) is participating, effective for due dates on or after June 18, 2026, in the Notice of Funding Opportunity Announcement (NOFO) RFA-HL-26-018 , "Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)l".
The following sections of RFA-HL-26-018 have been modified (changes shown in bold italics ) to reflect NIAID's participation in this NOFO: Part 1. Overview Information Components of Participating Organizations National Heart, Lung, and Blood Institute ( NHLBI ) National Institute of Allergy and Infectious Diseases ( NIAID ) Assistance Listing Number(s) 93. 837, 93.
233, 93. 838, 93. 839; 93.
855 Section VII. Agency Contacts Scientific/Research Contact(s) Division of Blood Diseases and Research Crystal Hill-Pryor, Ph. D.
, MPH National Heart, Lung and Blood Institute (NHLBI) Division of Cardiovascular Sciences National Heart, Lung and Blood Institute (NHLBI) National Center on Sleep Disorders Research National Heart, Lung and Blood Institute (NHLBI) Division of Lung Diseases National Heart, Lung and Blood Institute (NHLBI) Chemical Countermeasures Research Program ( CCRP ) National Institute of Allergy and Infectious Diseases ( NIAID ) Financial/Grants Management Contact(s) National Heart, Lung, and Blood Institute (NHLBI) National Institute of Allergy and Infectious Diseases ( NIAID ) All other aspects of the NOFO remain the same.
Please direct all inquiries to: National Heart, Lung and Blood Institute ( NHLBI ) Chemical Countermeasures Research Program ( CCRP ) National Institute of Allergy and Infectious Diseases ( NIAID ) Weekly TOC for this Announcement NIH... Turning Discovery Into Health ®
According to the current listing, eligibility includes: Small businesses, for-profit organizations, and other eligible entities. Confirm the full requirements in the official notice before applying.
The published deadline was March 31, 2025, which has passed. Check the official notice for any future application windows before investing time in a proposal.
RFA-HL-26-018: Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article